• Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer

    8 monthes ago - By Medscape

    Safety, efficacy and clinical outcomes were similar for Amgen's trastuzumab biosimilar ABP 980 and the trastuzumab reference product in women with HER2-positive early breast cancer in the LILAC study, researchers reported June 4 at the 2018 ASCO Annual Meeting.
    Reuters Health Information
    Read more ...